Advertisement

Tobacco as a Cardiovascular Risk Factor

  • Robyn Bergman Buchsbaum
  • Jeffrey Craig Buchsbaum
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Tobacco use in the form of cigarettes has long been established as a major risk factor for coronary heart disease (CHD). It is the most preventable cause of mortality. Each year, cigarette smoking causes more than 400,000 deaths in the United States alone, more than the number of American lives lost during World War I, Korea, and Vietnam combined (1,2). Not only does this modifiable behavior cause pain and suffering, but it poses a significant economic burden. Total US Medicaid expenses caused by tobacco use are more than $6 billion a year (3). Total direct health care costs are in excess of $75 billion a year. Indirect losses, usually because of lost productivity, increase that figure by another $80 billion a year (3,4). For every cigarette pack sold in the United States, the country spends approx $7.18 in health care-related and lost productivity costs (5). In the mid1990s, state attorneys general participated in legal action with tobacco companies in hopes of winning back money spent on Medicaid expenses. In 1998, an out-of-court settlement was reached giving states billions of dollars upfront and billions more in annual payments (6). Since then, most states have failed to allocate the Centers for Disease Control and Prevention-recommended funding for tobacco prevention, despite the fact that states are taking in record amounts of tobacco-generated revenue from the settlement and from increased cigarette taxes (7).

Keywords

Cigarette Smoking Smoking Cessation Nicotine Replacement Therapy Environmental Tobacco Smoke Passive Smoking 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fielding JE. Smoking: health effects and control. N Engl J Med 1985; 313: 491–498.PubMedCrossRefGoogle Scholar
  2. 2.
    Fielding J. Practical solutions to smoking control. Corp Comment 1985; 1: 46–49.PubMedGoogle Scholar
  3. 3.
    Centers for Disease Control and Prevention. Medical care expenditures attributable to cigarette smoking United States, 1993. MMWR 1994; 43: 469–472.Google Scholar
  4. 4.
    Centers for Disease Control and Prevention. Targeting Tobacco Use: The Nation’s Leading Cause of Death 2004, US Department of Health and Human Services, ed. 2004, US Government.Google Scholar
  5. 5.
    Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost and economic costs United States, 1995–1999. MMWR, 2002; 51: 300–303.Google Scholar
  6. 6.
    National Conference of State Legislatures. Summary of the Attorneys General Master Tobacco Settlement Agreement. 1999, US Government.Google Scholar
  7. 7.
    Campaign for Tobacco-Free Kids. A Broken Promise to Our Children: The 1998 Tobacco Settlement 6 Years Later. 2004.Google Scholar
  8. 8.
    US Department of Health and Human Services. Progress Review, Tobacco Use, ed. 2003.Google Scholar
  9. 9.
    US Department of Health and Human Services. Healthy People 2010 Goal 27-1 Reduce Tobacco Use by Adults, ed. 2005.Google Scholar
  10. 10.
    Office of Disease Prevention and Health Promotion. Healthy people 2000: midcourse review and 1995 revisions. 1995, US Department of Health and Human Services: Washington, DC.Google Scholar
  11. 11.
    Pierce JP, et al. Trends in cigarette smoking in the United States. Projections to the year 2000. JAMA 1989; 261: 61–65.PubMedCrossRefGoogle Scholar
  12. 12.
    Substance Abuse and Mental Health Service Administration. Results from the 2001 National Household Survey on Drug Abuse, US Department of Health and Human Services, ed. 2002.Google Scholar
  13. 13.
    Peto R, Lopez A, Boreham, J, et al. Mortality from smoking worldwide. Br Med Bull 1996; 52: 12–21.PubMedGoogle Scholar
  14. 14.
    Mahaney FX Jr. Oldtime ads tout health benefits of smoking: tobacco industry had doctors’ help. J Natl Cancer Inst 1994; 86: 1048–1049.PubMedCrossRefGoogle Scholar
  15. 15.
    Bartrip P. Pushing the weed: the editorializing and advertising of tobacco in the Lancet and the British Medical Journal, 1880-1958. Clio Med 1998; 46: 100–126; discussion 127–129.PubMedGoogle Scholar
  16. 16.
    DeNelsky G. Smoking: what it’s all about, what to do about it. in Preventive Cardiology and Rehabilitation Group Conference. Cleveland Clinic, 1998.Google Scholar
  17. 17.
    Terry LL. The Surgeon General’s first report on smoking and health. A challenge to the medical profession. NY State J Med 1983; 83: 1254–1255.Google Scholar
  18. 18.
    Campaign for Tobacco-Free Kids. Big Tobacco Still Targeting Kids, Special Report. 2005, Washington, DC.Google Scholar
  19. 19.
    Adams KF, et al. Acute elevation of blood carboxyhemoglobin to 6% impairs exercise performance and aggravates symptoms in patients with ischemic heart disease. J Am Coll Cardiol 1988; 12: 900–909.PubMedGoogle Scholar
  20. 20.
    Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29: 1422–1431.PubMedCrossRefGoogle Scholar
  21. 21.
    Johnstone RA, Plimmer JR. The chemical constituents of tobacco and tobacco smoke. Chem Rev 1959; 59: 885–936.CrossRefGoogle Scholar
  22. 22.
    Lekakis J, et al. Effects of acute cigarette smoking on endothelium-dependent arterial dilatation in normal subjects. Am J Cardiol 1998; 81: 1225–1228.PubMedCrossRefGoogle Scholar
  23. 23.
    Thomas CB, Murphy EA. Circulatory responses to smoking in healthy young men. Ann NY Acad Sci 1960; 90: 266–276.PubMedCrossRefGoogle Scholar
  24. 24.
    Tresch DD, Aronow WS. Smoking and coronary artery disease. Clin Geriatr Med 1996; 12: 23–32.PubMedGoogle Scholar
  25. 25.
    Nowak J, et al. Effect of nicotine infusion in humans on platelet aggregation and urinary excretion of a major thromboxane metabolite. Acta Physiol Scand 1996; 157: 101–107.PubMedCrossRefGoogle Scholar
  26. 26.
    Gleerup G, Winther K. Smoking further increases platelet activity in patients with mild hypertension. Eur J Clin Invest 1996; 26: 49–52.PubMedCrossRefGoogle Scholar
  27. 27.
    dePadua Mansur A, et al. Smoking and lipoprotein abnormalities on platelet aggregation in coronary heart disease. Int J Cardiol 1997; 62: 151–154.PubMedCrossRefGoogle Scholar
  28. 28.
    Hung J, et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432–2436.PubMedGoogle Scholar
  29. 29.
    Reinders JH, et al. Cigarette smoke impairs endothelial cell prostacyclin production. Arteriosclerosis 1986; 6: 15–23.PubMedGoogle Scholar
  30. 30.
    Esen AM, et al. Effect of smoking on endothelial function and wall thickness of brachial artery. Circ J 2004; 68: 1123–1126.PubMedCrossRefGoogle Scholar
  31. 31.
    Allen RA, Kluft C, Brommer EJ. Effect of chronic smoking on fibrinolysis. Arteriosclerosis 1985; 5: 443–450.PubMedGoogle Scholar
  32. 32.
    Rangemark C, Wennmalm A. Smoke-derived nitric oxide and vascular prostacyclin are unable to counteract the platelet effect of increased thromboxane formation in healthy female smokers. Clin Physiol 1996; 16: 301–315.PubMedGoogle Scholar
  33. 33.
    Ichiki K, et al. Longterm smoking impairs plateletderived nitric oxide release. Circulation 1996; 94: 3109–3114.PubMedGoogle Scholar
  34. 34.
    Randi ML, et al. Cerebral vascular accidents in young patients with essential thrombocythemia: relation with other known cardiovascular risk factors. Angiology 1998; 49: 477–481.PubMedCrossRefGoogle Scholar
  35. 35.
    Jensen OK, Ingerslev J. Increased p-homocysteine a risk factor for thrombosi. Ugeskr Laeger 1998; 160: 4405–4410.PubMedGoogle Scholar
  36. 36.
    Miller GJ, et al. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost 1998; 79: 549–553.PubMedGoogle Scholar
  37. 37.
    Nagai R. Cardiovascular research in the era of genome medicine and EBM. Rinsho Byori 2003; 51: 208–213.PubMedGoogle Scholar
  38. 38.
    Winkelmann BR, et al. Rationale and design of the LURIC study a resource for functional genomics, pharmacogenomics and longterm prognosis of cardiovascular disease. Pharmacogenomics 2001; 2 (1 Suppl): S1–73.PubMedCrossRefGoogle Scholar
  39. 39.
    Taylor BV, et al. Clinical and pathophysiological effects of active and passive smoking on the cardiovascular system. Can J Cardiol 1998; 14: 1129–1139.PubMedGoogle Scholar
  40. 40.
    Nelson E. The miseries of passive smoking. Hum Exp Toxicol 2001; 20: 61–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Sherman J, et al. Prenatal smoking and alterations in newborn heart rate during transition. J Obstet Gynecol Neonatal Nurs 2002; 31: 680–687.PubMedGoogle Scholar
  42. 42.
    Kahn A, et al. Sudden infant deaths: from epidemiology to physiology. Forensic Sci Int 2002; 130 (Suppl): S8–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Kannel WB, D’Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113: 1006–1010.PubMedCrossRefGoogle Scholar
  44. 44.
    Kannel WB. Update on the role of cigarette smoking in coronary artery disease. Am Heart J 1981; 101: 319–328.PubMedCrossRefGoogle Scholar
  45. 45.
    Cavender JB, et al. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow up. CASS Investigators. J Am Coll Cardiol 1992; 20: 287–294.PubMedCrossRefGoogle Scholar
  46. 46.
    Daly LE, et al. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. Br Med J (Clin Res Ed) 1983; 287: 324–326.CrossRefGoogle Scholar
  47. 47.
    Macdonald RG, et al. Patientrelated variables and restenosis after percutaneous transluminal coronary angioplasty a report from the M-HEART Group. Am J Cardiol 1990; 66: 926–931.PubMedCrossRefGoogle Scholar
  48. 48.
    Arora RR, et al. Restenosis after transluminal coronary angioplasty: a risk factor analysis. Cathet Cardiovasc Diagn 1990; 19: 17–22.PubMedCrossRefGoogle Scholar
  49. 49.
    Benchimol D, et al. Risk factors for progression of atherosclerosis six months after balloon angioplasty of coronary stenosis. Am J Cardiol 1990; 65: 980–985.PubMedCrossRefGoogle Scholar
  50. 50.
    Galan KM, et al. Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplasty. Am J Cardiol 1988; 61: 260–263.PubMedCrossRefGoogle Scholar
  51. 51.
    Myler RK, et al. Multiple vessel coronary angioplasty: classification, results, and patterns of restenosis in 494 consecutive patients. Cathet Cardiovasc Diagn 1987; 13: 1–15.PubMedCrossRefGoogle Scholar
  52. 52.
    Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115(1 Pt 2): 242–249.PubMedCrossRefGoogle Scholar
  53. 53.
    Glantz SA, Parmley WW. Passive smoking and heart disease. Mechanisms and risk. JAMA 1995; 273: 1047–1053.PubMedCrossRefGoogle Scholar
  54. 54.
    Kannel WB, D’Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992; 2: 457–466.PubMedCrossRefGoogle Scholar
  55. 55.
    Kawachi I, et al. A prospective study of passive smoking and coronary heart disease. Circulation 1997; 95: 2374–2379.PubMedGoogle Scholar
  56. 56.
    Dwyer T, et al. Evaluation of the Sydney “Quit. For Life” antismoking campaign. Part 2. Changes in smoking prevalence. Med J Aust 1986; 144: 344–347.PubMedGoogle Scholar
  57. 57.
    Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation 1991; 83: 1–12.Google Scholar
  58. 58.
    Glantz SA, Parmley WW. Passive smoking causes heart disease and lung cancer. J Clin Epidemiol 1992; 45: 815–819.PubMedCrossRefGoogle Scholar
  59. 59.
    Burghuber OC, et al. Platelet sensitivity to prostacyclin in smokers and nonsmokers. Chest 1986; 90: 34–38.PubMedGoogle Scholar
  60. 60.
    Davis JW, et al. Cigarette smoking induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med 1985; 105: 479–483.PubMedGoogle Scholar
  61. 61.
    Davis JW, et al. Effects of tobacco and nontobacco cigarette smoking on endothelium and platelets. Clin Pharmacol Ther 1985; 37: 529–533.PubMedCrossRefGoogle Scholar
  62. 62.
    Davis JW, et al. Lack of effect of aspirin on cigarette smokeinduced increase in circulating endothelial cells. Haemostasis 1987; 17: 66–69.PubMedGoogle Scholar
  63. 63.
    Howard G et al. Cigarette smoking and progression of atherosclerosis The Atherosclerosis Risk in Communities ARIC Study. JAMA 1998; 279] 119–124Google Scholar
  64. 64.
    US Public Health Service, Office of the Surgeon General. The health benefits of smoking cessation: Report of the Surgeon General. Washington, DC, 1990.Google Scholar
  65. 65.
    Panagiotakos DB, et al. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. Am J Med 2004; 116: 145–150.PubMedCrossRefGoogle Scholar
  66. 66.
    Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322: 213–217.PubMedCrossRefGoogle Scholar
  67. 67.
    Rosenberg L, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313: 1511–1514.PubMedCrossRefGoogle Scholar
  68. 68.
    Dobson AJ, et al. How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol 1991; 44: 1247–1253.PubMedCrossRefGoogle Scholar
  69. 69.
    Ayanian JZ, Cleary PD. Perceived risks of heart disease and cancer among cigarette smokers. JAMA 1999; 281: 1019–1021.PubMedCrossRefGoogle Scholar
  70. 70.
    US Department of Health and Human Services. Smoking cessation: clinical practice guideline. Department of Health and Human Services: Washington, DC, 1996.Google Scholar
  71. 71.
    Ockene JK, et al. Increasing the efficacy of physiciandelivered smoking interventions: a randomized clinical trial. J Gen Intern Med 1991; 6: 1–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Glynn TJ, Manley MW, Pechacek TF. Physicianinitiated smoking cessation program: the National Cancer Institute trials. Prog Clin Biol Res 1990; 339: 11–25.PubMedGoogle Scholar
  73. 73.
    Frank E, et al. Predictors of physician’s smoking cessation advice. JAMA 1991; 266: 3139–3144.PubMedCrossRefGoogle Scholar
  74. 74.
    Kottke TE, et al. Attributes of successful smoking cessation interventions in medical practice. A metaanalysis of 39 controlled trials. JAMA 1988; 259: 2883–2889.PubMedCrossRefGoogle Scholar
  75. 75.
    Kottke TE et al. A comparison of two methods to recruit physicians to deliver smoking cessation interventions. Arch Intern Med 1990; 150] 1477–1481Google Scholar
  76. 76.
    Kottke TE, et al. A controlled trial to integrate smoking cessation advice into primary care practice: Doctors Helping Smokers, Round III. J Fam Pract 1992; 34: 701–708.PubMedGoogle Scholar
  77. 77.
    Kottke TE. Smoking cessation therapy for the patient with heart disease. J Am Coll Cardiol 1993; 22: 1168–1169.PubMedCrossRefGoogle Scholar
  78. 78.
    Kottke TE. Observing the delivery of smokingcessation interventions. Am J Prev Med 1998; 14: 71–72.PubMedCrossRefGoogle Scholar
  79. 79.
    Prochaska JO, Goldstein MG. Process of smoking cessation. Implications for clinicians. Clin Chest Med 1991; 12: 727–735.PubMedGoogle Scholar
  80. 80.
    Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43: 289–294.PubMedGoogle Scholar
  81. 81.
    Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 2000; 45: 1196–1199.PubMedGoogle Scholar
  82. 82.
    Centers for Disease Control and Prevention. Reducing tobacco use: a report of the Surgeon General. Department of Health and Human Services US Government, 2000.Google Scholar
  83. 83.
    Kornitzer M, et al. A double blind study of 2 mg versus 4 mg nicotinegum in an industrial setting. J Psychosom Res 1987; 31: 171–176.PubMedCrossRefGoogle Scholar
  84. 84.
    Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. Annu Rev Public Health 2005; 26: 583–599.PubMedCrossRefGoogle Scholar
  85. 85.
    Tonnesen P, et al. Two and four mg nicotine chewing gum and group counseling in smoking cessation: an open, randomized, controlled trial with a 22 month followup. Addict Behav 1988; 13: 17–27.PubMedCrossRefGoogle Scholar
  86. 86.
    Benowitz NL, Jacob P 3rd, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 1987; 41: 467–473.PubMedCrossRefGoogle Scholar
  87. 87.
    Herrera N, et al. Nicotine gum, 2 and 4 mg, for nicotine dependence. A doubleblind placebocontrolled trial within a behavior modification support program. Chest 1995; 108: 447–451.Google Scholar
  88. 88.
    Lee EW, D’Alonzo GE. Cigarette smoking, nicotine addiction, and its pharmacologic treatment. Arch Intern Med 1993; 153: 34–48.PubMedCrossRefGoogle Scholar
  89. 89.
    Henningfield JE, et al. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA 1990; 264: 1560–1564.PubMedCrossRefGoogle Scholar
  90. 90.
    Fiore MC, et al. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 1994; 271: 1940–1947.Google Scholar
  91. 91.
    Wasley MA et al. The costeffectiveness of the nicotine transdermal patch for smoking cessation. Prev Med 1997; 26] 264–270Google Scholar
  92. 92.
    Hughes JR, et al. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281: 72–76.PubMedCrossRefGoogle Scholar
  93. 93.
    Schneider NG, et al. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet 1996; 31: 65–80.Google Scholar
  94. 94.
    Pfizer Inc. Nicotrol nasal spray prescribing information. Pfizer Consumer Healthcare, Morris Plains, NJ, 2005.Google Scholar
  95. 95.
    Sutherland G, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324–329.PubMedCrossRefGoogle Scholar
  96. 96.
    Hughes J. Dependence on and abuse of nicotine replacement: an update. In: N. Benowitz, ed. Nicotine Safety and Toxicity. New York, Oxford University Press, 1999, pp. 147–160.Google Scholar
  97. 97.
    Schuh KJ, et al. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology (Berl) 1997; 130: 352–361.CrossRefGoogle Scholar
  98. 98.
    Leischow SJ Nilsson F Franzon MA. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. Am J Health Behav 1996; 20] 364–371Google Scholar
  99. 99.
    Tonnesen P, et al. A doubleblind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269: 1268–1271.PubMedCrossRefGoogle Scholar
  100. 100.
    Glaxo Wellcome. Zyban prescribing information. Glaxo Wellcome:Research Triangle Park, NC, 1998.Google Scholar
  101. 101.
    Hurt RD et al. A comparison of sustainedrelease bupropion and placebo for smoking cessation. N Engl J Med 1997; 337] 1195–1202Google Scholar
  102. 102.
    Prochazka AV, et al. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med 1992; 152: 2065–2069.PubMedCrossRefGoogle Scholar
  103. 103.
    Prochazka AV, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158: 2035–2039.PubMedCrossRefGoogle Scholar
  104. 104.
    Edwards NB et al. Doxepin as an adjunct to smoking cessation a doubleblind pilot study. Am J Psychiatry 1989; 146] 373–376Google Scholar
  105. 105.
    Ferry L, Johnston JA. Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. Int J Clin Pract 2003; 57: 224–230.PubMedGoogle Scholar
  106. 106.
    Jorenby DE, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–691.PubMedCrossRefGoogle Scholar
  107. 107.
    Ascher JA, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395–401.PubMedGoogle Scholar
  108. 108.
    Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833–1838.PubMedCrossRefGoogle Scholar
  109. 109.
    GlaxoSmithKline Inc. Nicotine lozenge patient information. King of Prussia, PA, 2002.Google Scholar
  110. 110.
    Shiffman S, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162: 1267–1276.PubMedCrossRefGoogle Scholar
  111. 111.
    Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 2004; 99: 83–92.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Robyn Bergman Buchsbaum
    • 1
  • Jeffrey Craig Buchsbaum
    • 2
  1. 1.Formerly Affiliated with The Heart CenterThe Cleveland Clinic FoundationCleveland
  2. 2.Department of Radiation Oncology and Department of Pediatrics, Milton S. Hershey Medical CenterPenn State University College of MedicineHershey

Personalised recommendations